Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Janssen-Cilag International NV
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
Telaprevir Open-Label Study in Co-Infected Patients
The objective of this open-label safety study is to collect safety and tolerability data on telaprevir treatment in combination with Peg-IFNalfa and RBV in subjects with HIV/genotype 1 chronic HCV coi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
MAJ Il y a 5 ans
A Phase 2, Randomized Study of VELCADE® (bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who are Candidates for Autologous Transplantation
The primary objective of this study is to determine the overall combined complete response rate (CR rate) (defined in this protocol as the combination of complete response [CR, including sCR and nCR])...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants With Advanced Liver Disease El objetivo principal es determinar la eficacia de un régimen de tratamiento de 12 semanas de simeprevir en combinación con daclatasvir, medida por la RVS12 (respuesta virológica sostenida a las 12 semanas después del final del tratamiento [FT] real), en pacientes con infección crónica por el VHC de genotipo 1b no pretratados que presenten fibrosis avanzada o cirrosis compensada
To determine the efficacy of a 12-week treatment regimen of simeprevir in combination with daclatasvir, as measured by SVR12, in treatment-naïve, chronic HCV genotype 1b-infected subjects who have adv...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
A Phase 3 Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants with mHSPC Badanie kliniczne fazy 3 porównujące skojarzenie Apalutamidu i wytrzebienia farmakologicznego (ADT) z wytrzebieniem farmakologicznym (ADT) u pacjentów z rakiem gruczołu krokowego (mHSPC)
The primary objective is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for subjects ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
A Study of the Efect of JNJ-40346527 and Placebo in Patients with Active Rheumatoid Arthritis
The primary objectives are to assess the safety, tolerability, and efficacy (change from baseline in Disease Activity Score 28 [DAS28] using C-reactive protein [CRP]) of JNJ-40346527 200 mg/day (100 m...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
A Study of Doripenem in Cerebrospinal Fluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age
The primary objective of this study is to evaluate the penetration of doripenem in cerebrospinal fluid (CSF) after administration of doripenem to pediatric subjects less than 1 year of age with or wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 5 ans
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Moderate to Severe Knee or Hip Pain From Osteoarthritis
The primary objectives of the study are to evaluate the analgesic effect size over 12 weeks of several doses and dosage regimens of JNJ 42160443 compared with placebo in subjects with moderate to seve...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study, to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy
• To assess the effect of canagliflozin relative to placebo on HbA1c after 26 weeks of treatment. • To assess the safety and tolerability of canagliflozin
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
A Phase IIa Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of JNJ-38518168 in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy With Synovial Biopsy Substudy
To assess the safety, tolerability, and efficacy (in terms of change in DAS28 [using C-Reactive Protein (CRP)] from baseline) of JNJ-38518168 at a dose of 100 mg/day for up to 12 weeks compared to pla...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 5 ans
A Multicenter, Double-Blind, Parallel-Group Study to Evaluate Short-Term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1-to-11-Year-Old Pediatric Subjects with Endoscopically Proven GERD
The primary objectives of this study are to evaluate the efficacy(endoscopic/histological healing) and safety of 2 dose levels (0.5 mg/kg [10 mg max dose] and 1.0 mg/kg [20 mg max dose]) of a pediatri...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
4
5
6
7
8
9
10
11
12
13
Suivant